Cuicui Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cuicui Lin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chen Li
Department of Human Genetics, and Women’s Hospital, Zhejiang University School of Medicine, 310058 Hangzhou, Zhejiang, China
1 shared publication - Chunyan Wang
The Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China
1 shared publication - Huimei Zheng
Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, the Women's Hospital, Zhejiang University School of Medicine, China
1 shared publication - Lifeng Zhang
Department of Obstetrics Women′s Hospital Zhejiang University School of Medicine Hangzhou China zju.edu.cn
1 shared publication - Min-Xin Guan
Institute of Genetics, Zhejiang University, Hangzhou, China
1 shared publication - Xiaohang Yang
Institute of Genetics, Zhejiang University International School of Medicine, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Lipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models
Endometriosis is an estrogen‐dependent chronic inflammatory disease that affects approximately 10% of women of reproductive age and up to 50% of women with infertility. The heterogeneity of the disease makes accurate diagnosis and treatment a clinical challenge. In this study, we generated two models of endometriosis: the first in rats and the second using human ectopic endometrial stromal cells (HEcESCs) derived from the lesion tissues of endometriosis patients. We then applied resveratrol to assess its therapeutic potential. Resveratrol intervention had significant efficacy to attenuate lesion size and to rectify aberrant lipid profiles of model rats. Lipidomic analysis revealed significant lipidomic alterations, including notable increases of sphingolipids and decreases of both glycerolipids and most phospholipids. Upon resveratrol application, both proliferation capacity and invasiveness parameters decreased, and the early apoptosis proportion increased for HEcESCs. The activation of PPARα was also noted as a factor potentially contributing to recovery from endometriosis in both models. Our study provides valuable insight into the mechanisms of resveratrol in endometriosis and therefore strengthens the potential for optimizing resveratrol treatment for this disease.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessLipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models
Endometriosis is an estrogen‐dependent chronic inflammatory disease that affects approximately 10% of women of reproductive age and up to 50% of women with infertility. The heterogeneity of the disease makes accurate diagnosis and treatment a clinical challenge. In this study, we generated two models of endometriosis: the first in rats and the second using human ectopic endometrial stromal cells (HEcESCs) derived from the lesion tissues of endometriosis patients. We then applied resveratrol to assess its therapeutic potential. Resveratrol intervention had significant efficacy to attenuate lesion size and to rectify aberrant lipid profiles of model rats. Lipidomic analysis revealed significant lipidomic alterations, including notable increases of sphingolipids and decreases of both glycerolipids and most phospholipids. Upon resveratrol application, both proliferation capacity and invasiveness parameters decreased, and the early apoptosis proportion increased for HEcESCs. The activation of PPARα was also noted as a factor potentially contributing to recovery from endometriosis in both models. Our study provides valuable insight into the mechanisms of resveratrol in endometriosis and therefore strengthens the potential for optimizing resveratrol treatment for this disease.